Apogee Therapeutics, Inc. (NASDAQ:APGE) CEO Michael Thomas Henderson Sells 15,000 Shares

Apogee Therapeutics, Inc. (NASDAQ:APGE - Get Free Report) CEO Michael Thomas Henderson sold 15,000 shares of the firm's stock in a transaction dated Wednesday, January 8th. The shares were sold at an average price of $48.85, for a total value of $732,750.00. Following the completion of the transaction, the chief executive officer now owns 1,309,487 shares of the company's stock, valued at $63,968,439.95. The trade was a 1.13 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Michael Thomas Henderson also recently made the following trade(s):

• On Wednesday, December 4th, Michael Thomas Henderson sold 15,000 shares of Apogee Therapeutics stock. The shares were sold at an average price of $46.58, for a total value of $698,700.00.
• On Wednesday, November 6th, Michael Thomas Henderson sold 15,000 shares of Apogee Therapeutics stock. The shares were sold at an average price of $59.22, for a total transaction of $888,300.00.

Apogee Therapeutics Price Performance

NASDAQ:APGE traded down $8.16 during mid-day trading on Friday, reaching $41.05. The stock had a trading volume of 1,366,016 shares, compared to its average volume of 509,403. The stock has a 50-day simple moving average of $48.70 and a two-hundred day simple moving average of $48.90. The stock has a market capitalization of $1.85 billion, a PE ratio of -16.96 and a beta of 2.26. Apogee Therapeutics, Inc. has a 12 month low of $30.84 and a 12 month high of $72.29.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. Canaccord Genuity Group assumed coverage on shares of Apogee Therapeutics in a research note on Monday, November 25th. They issued a "buy" rating and a $89.00 target price for the company. Guggenheim reiterated a "buy" rating on shares of Apogee Therapeutics in a research note on Thursday, December 12th. Canaccord Genuity Group started coverage on shares of Apogee Therapeutics in a research note on Monday, November 25th. They issued a "buy" rating and a $89.00 target price for the company. Finally, Wedbush raised their price objective on shares of Apogee Therapeutics from $87.00 to $90.00 and gave the stock an "outperform" rating in a research report on Monday, December 2nd. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $89.71.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Point72 DIFC Ltd bought a new position in Apogee Therapeutics in the second quarter valued at approximately $660,000. Point72 Asset Management L.P. grew its stake in shares of Apogee Therapeutics by 162.7% during the third quarter. Point72 Asset Management L.P. now owns 707,268 shares of the company's stock worth $41,545,000 after buying an additional 438,036 shares during the last quarter. XTX Topco Ltd bought a new stake in shares of Apogee Therapeutics during the second quarter worth $706,000. Victory Capital Management Inc. grew its stake in shares of Apogee Therapeutics by 56.8% during the second quarter. Victory Capital Management Inc. now owns 156,266 shares of the company's stock worth $6,149,000 after buying an additional 56,607 shares during the last quarter. Finally, Waypoint Capital Advisors LLC bought a new stake in shares of Apogee Therapeutics during the third quarter worth $36,835,000. 79.04% of the stock is owned by institutional investors.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.